Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

990
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

909
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
909
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients.

Journal of the American Heart Association·2026
Same author

Phenotypic clustering identifies heterogeneous cardiovascular risk among patients with elevated lipoprotein(a).

Scientific reports·2026
Same author

Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.

Drug design, development and therapy·2026
Same author

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.

Journal of the American Heart Association·2026
Same author

Visit-to-visit systolic blood pressure variability and risk of severe hypertensive episodes in a multicenter cohort.

American journal of hypertension·2026
Same author

Variability of SBP and cardiovascular outcomes in hypertensive patients.

BMC cardiovascular disorders·2026

Related Experiment Video

Updated: Apr 16, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.6K

Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic

Soon Jun Hong1, Seung Cheol Choi, Jae Young Cho

  • 1Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital.

Circulation Journal : Official Journal of the Japanese Circulation Society
|March 5, 2015
PubMed
Summary
This summary is machine-generated.

Pioglitazone treatment in type 2 diabetes patients significantly reduced neointimal hyperplasia after stenting. This was associated with increased circulating microRNA-24 levels, suggesting its potential as a predictor for neointimal hyperplasia.

More Related Videos

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

2.0K
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

4.4K

Related Experiment Videos

Last Updated: Apr 16, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.6K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

2.0K
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

4.4K

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Molecular Biology

Background:

  • Aberrant microRNA expression is linked to neointimal hyperplasia (NIH) in type 2 diabetes.
  • Understanding the role of microRNAs in NIH is crucial for developing targeted therapies.

Purpose of the Study:

  • To compare the effects of pioglitazone on coronary NIH and microRNA changes in type 2 diabetic patients.
  • To evaluate pioglitazone's impact on vascular function and inflammation markers.

Main Methods:

  • Prospective study with type 2 diabetic patients undergoing coronary stenting.
  • Randomized assignment to pioglitazone or control groups (n=36 each) for 9-month follow-up.
  • Primary endpoints: changes in neointimal volume (OCT) and circulating microRNAs (miR-17, -24, -92a, -126, -145).

Main Results:

  • Pioglitazone significantly reduced neointimal volume compared to the control group (25.02±17.78 mm³ vs. 55.10±30.01 mm³, P<0.001).
  • Circulating microRNA-24 levels significantly increased in the pioglitazone group (0.264±0.084 vs. 0.006±0.030, P<0.001).
  • Improved brachial artery flow-mediated dilation and reduced inflammatory markers (IL-6, TNF-α, sVCAM-1) were observed with pioglitazone.

Conclusions:

  • Pioglitazone effectively decreases neointimal hyperplasia in type 2 diabetic patients post-stenting.
  • Increased circulating microRNA-24 levels correlate with reduced NIH, suggesting its potential as a predictive biomarker.